4BIO Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)Amgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsFast Track InitiativeRemiges Ventures, Inc.Astellas Venture Management LLCAxil CapitalDCI Partners Co. Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.